SCHEMBL21628556

SCHEMBL21628556

CCOC(=O)c1cnc(Oc2ccc(C3CCC3)cc2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAOB P27338 3/20 0.39
LMNA P02545 2/20 0.38
CYP1A2 P05177 2/20 0.38
POLB P06746 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TSHR P16473 1/20 0.38
CYP19A1 P11511 2/20 0.38
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP9 Q86TI2 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
PDE4B Q07343 1/20 0.37
P2RX3 P56373 1/20 0.37
F10 P00742 1/20 0.37
S1PR1 P21453 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21628453 0.98 MAPT (0.43) MAPTALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL21628597 0.97 ALDH1A1 (0.45) MAPTALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL21628680 0.97 ALDH1A1 (0.45) MAPTALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL21628869 0.96 MAOB (0.40) MAPTALDH1A1SMN1; SMN2MAOBLMNA
SCHEMBL21628393 0.88 ALOX5AP (0.45) MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL21628687 0.86 ALOX5AP (0.43) MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL21628488 0.85 SMN1; SMN2 (0.42) MAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL21628383 0.85 SMN1; SMN2 (0.42) MAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL21628405 0.84 FEN1 (0.42) SMN1; SMN2POLBL3MBTL1
SCHEMBL21628659 0.84 MAOB (0.52) MAPTALDH1A1MAOBLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US disclosed
US-20230406814-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-12-21 US disclosed
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-05-18 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-20220348535-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2022-11-03 US disclosed
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2021-04-15 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK MAPT 2272/4885ALDH1A1 717/4885SMN1; SMN2 796/4885
US-20220348535-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK MAPT 2272/4885ALDH1A1 717/4885SMN1; SMN2 796/4885
US-11591289-B2 Aromatic compounds AHR, TYR, MUSK MAPT 2195/4885ALDH1A1 900/4885SMN1; SMN2 1107/4885
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK MAPT 2272/4885ALDH1A1 717/4885SMN1; SMN2 796/4885
US-12600696-B2 Aromatic compounds CCR1, CCRL2, AHR MAPT 4404/4885ALDH1A1 929/4885SMN1; SMN2 919/4885
US-20230406814-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK MAPT 2272/4885ALDH1A1 717/4885SMN1; SMN2 796/4885
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK MAPT 2272/4885ALDH1A1 717/4885SMN1; SMN2 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.